• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

(CDK9-IN-16)

1

Identification

CDK9-IN-16 CDK9-IN-16
Name CDK9-IN-16
Formula C23H34ClN5O2S
MW 480.07
CAS No.
EINECS
Smiles [[email protected]@H]1(NC2=NC=C(Cl)C(C3=CSC(NCC4CCOCC4)=N3)=C2)CC[[email protected]@H](NCCOC)CC1 |&1:0,24|
Synonyms Compound 21
InChI InChI=1S/C23H34ClN5O2S/c1-30-11-8-25-17-2-4-18(5-3-17)28-22-12-19(20(24)14-26-22)21-15-32-23(29-21)27-13-16-6-9-31-10-7-16/h12,14-18,25H,2-11,13H2,1H3,(H,26,28)(H,27,29)/t17-,18-
2

Introduction

CDK9-IN-16 (Compound 21) is a highly selective and potent CDK9 kinase inhibitor with an IC50 of 0.002±0.0002 μM. CDK9 is a key regulator of transcription elongation in eukaryotic cells and has been considered as a potential drug target for several diseases including cardiac hypertrophy and certain cancers such as a variety of blood cancers as well as solid tumors.

Background Information

3

Protocol(Only for Reference)

Cell Experiment

Animal Experiment

4

Physical and Chemical Properties

Appearance: EBNumber:EB100166990

Storage condition

Solubility

5

Mechanism and Indication

Signaling Pathways Cell Cycle/DNA Damage
Target CDK
Research Area Cancer
Indications
6

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
7

Safety Data of CDK9-IN-16

8

Spectral Information

9

Suppliers List

Company Price and Availability Country/Region
AMEDCHEM CHINA
10

Related Products

Other Forms of

Name CAS No Formula MW

Recommended Compounds in CDK

Name CAS No Formula MW
LY2857785 1619903-54-6 C26H36N6O 448.6
THZ2 1604810-84-5 C31H28ClN7O2 566.0527
Palbociclib (isethionate) 827022-33-3 C26H35N7O6S 573.66
CDK9-IN-6 1391855-95-0 C27H37ClN6O2 513.07468
ML167 1285702-20-6 C19H17N3O3 335.36
AMG 925 1401033-86-0 C26H29N7O2 471.55
LDC000067 1073485-20-7 C18H18N4O3S 370.43
LEE011 (succinate hydrate) 1374639-79-8 C27H38N8O6X 570.64
LEE011 (succinate) 1374639-75-4 C27H36N8O5 552.63
LEE011 (hydrochloride) 1211443-80-9 C23H31ClN8O 471.0
LEE011 1211441-98-3 C23H30N8O 434.54
WHI-P180 (hydrochloride) 153437-55-9 C16H16ClN3O3 333.77
Wogonin 632-85-9 C16H12O5 284.26
1-NM-PP1 221244-14-0 C20H21N5 331.41
WHI-P180 211555-08-7 C16H15N3O3 297.31
THZ1 1604810-83-4 C31H28ClN7O2 566.05
Senexin A 1366002-50-7 C17H14N4 274.32
CDK4-IN-1 1256963-02-6 C22H29ClN8 440.97
Palbociclib (hydrochloride) 827022-32-2 C24H30ClN7O2 483.99
Purvalanol B 212844-54-7 C20H25ClN6O3 432.9

Recommended Compounds in Same Indication

Name CAS No Formula MW
11

Route of Synthesis

12

References

13

More Information

CDK9-IN-16

Tags: buy CDK9-IN-16 IC50 | CDK9-IN-16 price | CDK9-IN-16 cost | CDK9-IN-16 solubility | CDK9-IN-16 purchase | CDK9-IN-16 manufacturer | CDK9-IN-16 research buy | CDK9-IN-16 order | CDK9-IN-16 MSDS | CDK9-IN-16 chemical structure | CDK9-IN-16 Storage condition | CDK9-IN-16 molecular weight | CDK9-IN-16 mw | CDK9-IN-16 datasheet | CDK9-IN-16 supplier | CDK9-IN-16 cell line | CDK9-IN-16 NMR | CDK9-IN-16 MS | CDK9-IN-16 IR | CDK9-IN-16 solubility | CDK9-IN-16 Safe information | CDK9-IN-16 Qc and Spectral Information | CDK9-IN-16 Clinical Information | CDK9-IN-16 Clinical Trial | CDK9-IN-16 Route of Synthesis | CDK9-IN-16 storage condition | CDK9-IN-16 diseases and conditions | CDK9-IN-16 flash point | CDK9-IN-16 boiling point | CDK9-IN-16 melting point | CDK9-IN-16 storage condition | CDK9-IN-16 brand